Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Wistron | Pfizer | |
|---|---|---|
| Moat rating | none The 2025 annual report (English translation filed with TWSE 2026-04-28) shows scale without a protected return: revenue of NT$2.1865 trillion, up 108%, at a gross profit margin of 6.1% and a consolidated operating profit margin of 3.6%, with gross profit up 59.33% against net revenues up 108.39%. The report's own list of unfavorable factors opens with "Intense Price Competition and Declining Gross Profit Margins" and says the IT industry, "with its relatively low barriers to entry, has attracted numerous manufacturers, leading to fierce competition", while its key-buyer table puts Buyer A at 39.32%, Buyer E at 21.21% and Buyer I at 12.81% of 2025 net sales. A large, competitive incumbent whose own filing concedes the entry barriers are relatively low: no moat is claimable. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | none The report's "Competitive Niches" section lists operating capabilities rather than a durable barrier: an R&D team of "over 5,600 people", manufacturing bases in Taiwan, U.S.A., China, Mexico, Czech Republic, Vietnam and Malaysia, lean manufacturing, product quality, supplier relationships, global logistics and an experienced management team. None of these is a patent position or a customer lock-in: R&D expenses were 1.43% of 2025 revenue, the Company reports 120 U.S. and 122 Taiwan patents granted in 2025, and the niche section's description of brand clients "each comprising an equal share of our sales" sits beside a key-buyer table in which a single buyer took 39.32% of 2025 net sales. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | at parity Citing MIC (February 2026), the report puts the Company at approximately 18% of the roughly 135,350K notebooks, 24% of the 39,711K desktops and 22% of the 12,370K servers manufactured in Taiwan in 2025, and lists it among the major Taiwan ODMs in every category it charts (notebooks with Quanta, Compal, Inventec and Pegatron; servers with Hon Hai, Quanta, Inventec and MiTAC). It describes this only as "considerable market competitiveness" and claims no first-place rank. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak 2025 gross profit margin was 6.1% and consolidated operating profit margin 3.6%; gross profit rose 59.33% while net revenues rose 108.39%, so the margin narrowed. The report's first unfavorable factor is "Intense Price Competition and Declining Gross Profit Margins", and three buyers accounted for 39.32%, 21.21% and 12.81% of 2025 net sales. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Wistron is a Taiwanese ODM whose business, per its 2025 annual report, "primarily covers the R&D, manufacturing, testing and after-sales services" of servers and AI computing devices, notebooks, desktops, monitors and other electronics, with 3C electronics at 98.5% of 2025 sales. Revenue more than doubled to NT$2.1865 trillion on what the Chairman's letter calls "triple-digit percentage growth in revenue from AI and general-purpose servers", and the report cites MIC data placing the Company at approximately 18% of Taiwan-made notebooks, 24% of desktops and 22% of servers in 2025. Against that, the gross profit margin was 6.1%, the report's own unfavorable factors name intense price competition, declining gross margins and relatively low barriers to entry, and three buyers took 39.32%, 21.21% and 12.81% of 2025 net sales. The long-term plan is to expand the proportion of higher-margin products such as AI computing devices and servers, and the manufacturing policy aims automation and AI-driven intelligent manufacturing at "higher-complexity, technically demanding product segments — expanding gross margins" — a stated path toward an advantage, not evidence that one exists yet. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Contract designer-manufacturer for brand and cloud customers: the report describes "professional OEM services supporting clients with world renowned brands", lists CPUs, SSDs and DRAM as main materials, and among its 2025 R&D results lists GPU servers supporting NVIDIA B300, AMD MI355 and Intel Gaudi 3. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
| Long-horizon vote | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |